Market Place
Sourcing Support
All News #Library
Biotech
Nanoscope Set to Join Eyecelerator and ARVO 2026 Annual Meetings
23 Apr 2026 //
PR NEWSWIRE
Nanoscope Therapeutics Publishes Study On Vision Assessment
23 Mar 2026 //
PR NEWSWIRE
Nanoscope Secures U.S. Patent for Opsin Vision Platform
07 Jan 2026 //
PR NEWSWIRE
Nanoscope Presents at 44th JP Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Nanoscope Therapeutics Showcased In Multiple Advanced Therapies
17 Nov 2025 //
PR NEWSWIRE
Nanoscope Reports 5-Year Safety From Ph 1/2a MCO-010 RP Study
04 Nov 2025 //
PR NEWSWIRE
Nanoscope Unveils 3-Year REMAIN Trial Results for Retinitis
26 Aug 2025 //
PR NEWSWIRE
Nanoscope Publishes Ph 2 Starlight Study in Stargardt Disease
14 Aug 2025 //
PR NEWSWIRE
Nanoscope Shares MOA Data on Opsin Technology
22 Jul 2025 //
PR NEWSWIRE
Nanoscope Forms Advisory Panel for Eye Disease R&D
26 Jun 2025 //
PR NEWSWIRE
Nanoscope Therapeutics to Present Research at ASGCT 2025 Meeting
12 May 2025 //
PR NEWSWIRE
Ramesh Arjunji, PhD, Joins Nanoscope as EVP, Value and Access
05 Mar 2025 //
PR NEWSWIRE
Nanoscope Therapeutics to Present at BIO CEO & Investor Conference
06 Feb 2025 //
PR NEWSWIRE
Ray Kaczmarek Joins Nanoscope as Chief Technical Officer
05 Dec 2024 //
PR NEWSWIRE
Nanoscope Publishes Breakthrough On MCO-010 And Neurodegeneration
21 Oct 2024 //
PR NEWSWIRE
Nanoscope preps filing for retinitis pigmentosa gene therapy
26 Mar 2024 //
PHARMAPHORUM
Nanoscope eyes market after phase 2b retinal disease data drop
26 Mar 2024 //
FIERCE BIOTECH
Nanoscope Announces Presentation of Key Results Ph2b RESTORE Trial of MCO-010
27 Apr 2023 //
PR NEWSWIRE
Nanoscope Announces Positive Results from Phase 2b RESTORE Trial of MCO-010
30 Mar 2023 //
PR NEWSWIRE
Nanoscope`s gene therapy boosts vision function in phase 2 test
30 Mar 2023 //
FIERCE BIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.